Impaktované publikace
Saussele, S.; Richter, J.; Guilhot, J.; Gruber, F.X.; Hjorth-Hansen, H.; Almeida, A.; Janssen, J.J.W.M.; Mayer, J.; Koskenvesa, P.; Panayiotidis, P.; Olsson-Strömberg, U.; Martinez-Lopez, J.; Rousselot, P.; Vestergaard, H.; Ehrencrona, H.; Kairisto, V.; Machová Poláková, K.; Müller, M.C.; Mustjoki, S.; Berger, M.G.; Fabarius, A.; Hofmann, W.-K.; Hochhaus, A.; Pfirrmann, M.; Mahon, F.-X.; Ossenkoppele, G.; Pagoni, M.N.; Söderlund, S.; Escoffre-Barbe, M.; Etienne, G.; Dengler, J.; Huguet, F.; von Bubnoff, N.; Klamova, H.; et al.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
[rok vydání 2018, impact factor 35.386 ]
Machova Polakova, K.; Zizkova, H.; Zuna, J.; Motlova, E.; Hovorkova, L.; Gottschalk, A.; Glauche, I.; Koblihova, J.; Pecherkova, P.; Klamova, H.; Stastna Markova, M.; Srbova, D.; Benesova, A.; Polivkova, V.; et al.
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
[rok vydání 2020, impact factor 11.528 ]
Polivkova, V.; Benesova, A.; Zizkova, H.; Koblihova, J.; Curik, N.; Motlova, E.; Klamova, H.; Salek, C.; Machova Polakova, K.
Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells
[rok vydání 2021, impact factor 11.528 ]
Porkka, K.; Koskenvesa, P.; Lundán, T.; Rimpiläinen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Höglund, M.; Klamová, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R.F.; Elonen, E.; Paquette, R.; Zwaan, C.M.; Lee, F.Y.
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
[rok vydání 2008, impact factor 10.432]
Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Brouckova, A.; Horner, D.; Iacono, M.; Castagnetti, F.; Gugliotta, G.; Palandri, F.; Papayannidis, C.; Iacobucci, I.; Venturi, C.; Bochicchio, M.T.; Klamova, H.; Cattina, F.; Russo, D.; Bresciani, P.; Binotto, G.; Giannini, B.; Kohlmann, A.; Haferlach, T.; Roller, A.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
[rok vydání 2013, impact factor 9.775 ]
Moravcová, J.; Nádvorníková, S.; Lukášová, M.; Klamová, H.
Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia
[rok vydání 2006, impact factor 8.782]
Vonka, V.; Humlova, Z.; Klamova, H.; Kujovska-Krcmova, L.; Petrackova, M.; Hamsikova, E.; Krmencikova-Fliegl, M.; Duskova, M.; Roth, Z.
Kynurenine and uric acid levels in chronic myeloid leukemia patients
[rok vydání 2014, impact factor 7.644 ]
Srutova, K.; Curik, N.; Burda, P.; Savvulidi, F.; Silvestri, G.; Trotta, R.; Klamova, H.; Pecherkova, P.; Sovova, Z.; Koblihova, J.; Stopka, T.; Perrotti, D.; Machova Polakova, K.
BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
[rok vydání 2018, impact factor 7.570 ]
Curik, N.; Polivkova, V.; Burda, P.; Koblihova, J.; Laznicka, A.; Kalina, T.; Kanderova, V.; Brezinova, J.; Ransdorfova, S.; Karasova, D.; Rejlova, K.; Bakardjieva, M.; Kuzilkova, D.; Kundrat, D.; Linhartova, J.; Klamova, H.; Salek, C.; Klener, P.; Hrusak, O.; Machova Polakova, K.
Somatic mutations in oncogenes are in chronic myeloid leukemia acquired de novo via deregulated base-excision repair and alternative non-homologous end joining
[rok vydání 2021, impact factor 6.244 ]
Jaruskova, M.; Curik, N.; Hercog, R.; Polivkova, V.; Motlova, E.; Benes, V.; Klamova, H.; Pecherkova, P.; Belohlavkova, P.; Vrbacky, F.; Machova Polakova, K.
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
[rok vydání 2017, impact factor 6.217 ]
Racil, Z.; Koritakova, E.; Sacha, T.; Klamova, H.; Belohlavkova, P.; Faber, E.; Rea, D.; Malaskova, L.; Prochazkova, J.; Zackova, D.; Voglova, J.; Waclaw, J.; Cetkovsky, P.; Zak, P.; Mayer, J.
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy
[rok vydání 2018, impact factor 6.137 ]
Linhartova, J.; Hovorkova, L.; Soverini, S.; Benesova, A.; Jaruskova, M.; Klamova, H.; Zuna, J.; Machova Polakova, K.
Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing
[rok vydání 2015, impact factor 5.888 ]
Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Linhartova, J.; Castagnetti, F.; Gugliotta, G.; Papayannidis, C.; Mancini, M.; Klamova, H.; Salvucci, M.; Crugnola, M.; Iurlo, A.; Albano, F.; Russo, D.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
[rok vydání 2016, impact factor 5.168 ]
Zackova, D.; Klamova, H.; Dusek, L.; Muzik, J.; Machova Polakova, K.; Moravcova, J.; Jurcek, T.; Dvorakova, D.; Racil, Z.; Pospisil, Z.; Oltova, A.; Michalova, K.; Brezinova, J.; Razga, F.; Doubek, M.; Cetkovsky, P.; Trneny, M.; Mayer, J.
Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
[rok vydání 2010, impact factor 4.671 ]
Machová Poláková, K.; Lopotová, T.; Klamová, H.; Burda, P.; Trněný, M.; Stopka, T.; Moravcová, J.
Expression patterns of microRNAs associated with CML phases and their disease related targets
[rok vydání 2011, impact factor 3.993 ]
Racil, Z.; Klamova, H.; Voglova, J.; Faber, E.; Razga, F.; Zackova, D.; Buresova, L.; Cetkovsky, P.; Mayer, J.
Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia
[rok vydání 2010, impact factor 3.576]
Pavlik, T.; Janousova, E.; Mayer, J.; Indrak, K.; Jarosova, M.; Klamova, H.; Zackova, D.; Voglova, J.; Faber, E.; Karas, M.; Machova Polakova, K.; Racil, Z.; Demeckova, E.; Demitrovicova, L.; Tothova, E.; Chudej, J.; Markuljak, I.; Cmunt, E.; Kozak, T.; Muzik, J.; Dusek, L.
Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications
[rok vydání 2013, impact factor 3.477 ]
Zackova, D.; Klamova, H.; Belohlavkova, P.; Stejskal, L.; Necasova, T.; Semerad, L.; Weinbergerova, B.; Srbova, D.; et al.
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
[rok vydání 2020, impact factor 3.280 ]
Smetana, K.; Klamová, H.; Pluskalová, M.; Stöckbauer, P.; Hrkal, Z.:
To the intranucleolar translocation of AgNORs in leukemic early granulocytic and plasmacytic precursors.
[rok vydání 2006, impact factor 3.220]
Haškovec, C.; Ponzetto, C.; Polák, J.; Maritano, D.; Zemanová, Z.; Serra, A.; Michalová, K.; Klamová, H.; Čermák, J.; Saglio, G.
P230 BCR/ABL protein may be associated with an acute leukaemia phenotype
[rok vydání 2006, impact factor 3.209]